AccuVein receives QTDP grant for AV300 vein illumination system

AccuVein LLC, the developer of the first non-contact, handheld vein illumination system, announced today that it had been awarded the maximum grant amount from the Qualifying Therapeutic Discover Project (QTDP) program.  This Federal grant program supports projects that show significant potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of health care costs.

AccuVein's AV300 helps health care professionals locate veins for blood draw, IV infusion and blood donation by projecting a pattern of light on patient's skin that reveals the position of underlying veins.  This 10-ounce, hand-held device is available with a range of hands-free options so that it can quickly free the practitioner's hands to perform the venipuncture.  It is the first and only system of its kind.

"Hospitals are adopting vein visualization as the standard-of-care for venipuncture as a tool to reduce error, reduce cost and increase patient satisfaction," said AccuVein engineering vice president Joe Zott.  "Winning this grant will support our continued investment in delivering the best vein illumination system in the market."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Elevated blood glucose levels increase early-onset colorectal cancer risk